CTRI/2020/12/029814已完成未知
intedanib Vs Pirfenidone in management of Covid19 related lung abnormality
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All cases of covid 19 pneumonia who were diagnosed as COVID positive >=15 days back or antibody positive and continue to be breathless symptomatically, have SPo2 <=96%, CT-severity score >=10 and CORADS-4/5/6
排除标准
- •-Patients having other interstitial lung diseases.
- •- Patient having CKD or creatinine clearance <30 and CLD with deranged LFT will be excluded.
- •-Not fulfilling the criteria for study
- •-Not giving consent for study.
研究者
相似试验
尚未招募
3 期
Pirfenidone for COVID-19 related lung fibrosisCTRI/2021/03/032199Anant Mohan
已完成
3 期
Effect of interfron in the treatment of covidCovid pneumonia.Coronavirus as the cause of diseaseB97.2IRCT20230930059562N1Imam hossein hospital80
招募中
不适用
The clinical impact of Nintedanib and Pirfenidone on pulmonary circulation of interstitial pneumonia: A Hyogo-IP multicenter prospective observational studyInterstitial pneumoniaJPRN-UMIN000043384Shinko Hospital75
已完成
不适用
Treatment With Pirfenidone for COVID-19 Related Severe ARDSCovid19ARDSNCT04653831Soroka University Medical Center26
招募中
3 期
Pirfenidone in Post COVID lung disease: Randomised controlled studyCTRI/2021/09/036442Sryma PB